Skip to main content
Clinical Trials/ISRCTN91141124
ISRCTN91141124
Active, not recruiting
Phase 3

Premature Ovarian Insufficiency Study of Effectiveness of hormonal therapy

niversity College London0 sites480 target enrollmentSeptember 9, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity College London
Enrollment
480
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2021
End Date
November 30, 2029
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
niversity College London

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 03/01/2024:
  • 1\. Diagnosis of POI (based on NICE guidelines) or with an established diagnosis of POI (e.g. Turner Syndrome, surgical menopause)
  • 2\. Will be aged older than 18 and less than 40 years at randomisation
  • 3\. Not intending to become pregnant within 12 months
  • 4\. Not taken any HRT, COC or testosterone treatment for the last 4 weeks or willing to stop HRT/COC/testosterone treatment for a minimum period of 4 weeks prior to randomisation
  • 5\. Must provide written/electronic informed consent
  • Previous inclusion criteria:
  • 1\. Diagnosis of POI
  • 2\. Will be aged older than 18 and less than 40 years at randomisation
  • 3\. Not intending to become pregnant within 12 months

Exclusion Criteria

  • Current exclusion criteria as of 03/01/2024:
  • 1\. Contraindications to HRT or COC
  • 2\. Taking other drugs affecting BMD e.g. bisphosphonates and long\-term use of systemic corticosteroids (dietary supplements e.g. Vitamin D, calcium and short course of corticosteroids are permitted)
  • 3\. Receiving estrogens for puberty induction
  • 4\. Participation in a clinical research study (currently or in the last 3 months) involving testosterone treatments or novel HRT formulations
  • Previous exclusion criteria:
  • 1\. Contraindications to HRT or COC
  • 2\. Taking other drugs affecting BMD e.g. bisphosphonates and long\-term use of systemic corticosteroids (dietary supplements e.g. Vitamin D, calcium and short course of corticosteroids are permitted)
  • 3\. Receiving sex steroid hormones for puberty induction
  • 4\. Participation in a clinical research study (currently or in the last 3 months) involving testosterone treatments or novel HRT formulations

Outcomes

Primary Outcomes

Not specified

Similar Trials